ATE340853T1 - Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung - Google Patents

Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung

Info

Publication number
ATE340853T1
ATE340853T1 AT01914236T AT01914236T ATE340853T1 AT E340853 T1 ATE340853 T1 AT E340853T1 AT 01914236 T AT01914236 T AT 01914236T AT 01914236 T AT01914236 T AT 01914236T AT E340853 T1 ATE340853 T1 AT E340853T1
Authority
AT
Austria
Prior art keywords
mutant gene
dna vaccination
subunity
adjuvants
asn
Prior art date
Application number
AT01914236T
Other languages
English (en)
Inventor
Young Chul Sung
Sung Hee Lee
Sang Jun Ha
Man Ki Song
Jun Pohang Chang
Original Assignee
Genexine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR10-2001-0012987A external-priority patent/KR100399728B1/ko
Application filed by Genexine Co Ltd filed Critical Genexine Co Ltd
Application granted granted Critical
Publication of ATE340853T1 publication Critical patent/ATE340853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT01914236T 2000-03-15 2001-03-15 Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung ATE340853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000013133 2000-03-15
KR10-2001-0012987A KR100399728B1 (ko) 2000-03-15 2001-03-13 ＩＬ-12 활성을 증가시키는 ＩＬ-12ｐ40 소단위체돌연변이 유전자 및 이를 ＤＮＡ 백신 면역증강제로이용하는 용도

Publications (1)

Publication Number Publication Date
ATE340853T1 true ATE340853T1 (de) 2006-10-15

Family

ID=36763001

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01914236T ATE340853T1 (de) 2000-03-15 2001-03-15 Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung

Country Status (10)

Country Link
US (2) US7253151B2 (de)
EP (1) EP1268759B1 (de)
JP (1) JP4180826B2 (de)
CN (1) CN1281748C (de)
AT (1) ATE340853T1 (de)
AU (2) AU3958101A (de)
CA (1) CA2402213C (de)
DE (1) DE60123400T2 (de)
ES (1) ES2272448T3 (de)
WO (1) WO2001068802A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2294213C1 (ru) * 2005-06-27 2007-02-27 Российская академия медицинских наук Государственное учреждение научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова (ГУ НИИВС им. И.И. Мечникова РАМН) Способ вакцинации против гепатита "в" детей со сниженной иммунореактивностью
KR100788930B1 (ko) * 2006-04-18 2007-12-27 포항공과대학교 산학협력단 항암 조성물
WO2007137328A1 (en) * 2006-05-26 2007-12-06 Apollo Life Sciences Limited An isolated il-12 molecule or chimeric molecules thereof
CN101935687B (zh) * 2009-06-29 2012-11-07 中国科学院上海生命科学研究院 用IL-12p40 siRNA促进肝再生
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
WO2016048903A1 (en) * 2014-09-22 2016-03-31 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
SG11201805162VA (en) * 2015-12-18 2018-07-30 Oncosec Medical Inc Plasmid constructs for heterologous protein expression and methods of use
DK3458083T5 (da) 2016-05-18 2024-10-21 Modernatx Inc Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf
CA3031955A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
KR102286397B1 (ko) * 2018-02-02 2021-08-05 주식회사 에스엘백시젠 신규 백신 면역보조제
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CN109517052A (zh) * 2018-12-04 2019-03-26 江苏禄亿生生物科技有限公司 一种il-12蛋白突变体及其制备方法和应用、nk细胞培养体系和培养nk细胞的方法
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
JP2025503454A (ja) * 2021-12-17 2025-02-04 ウィリアム マーシュ ライス ユニバーシティ Ｉｌ－１２を発現するカプセル化細胞及びその使用
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013268A (en) * 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
EP0818534A1 (de) * 1996-07-12 1998-01-14 Janssen Pharmaceutica N.V. Menschliche Interleukine-12 Genexpressions-regulierende Sequenzen
US6517839B1 (en) * 1997-07-18 2003-02-11 The Regents Of The University Of California Methods for inducing interleukin-12 and a type1/Th1 T-cell response

Also Published As

Publication number Publication date
JP2003526360A (ja) 2003-09-09
AU2001239581B2 (en) 2006-01-05
WO2001068802A3 (en) 2002-02-21
US7910564B2 (en) 2011-03-22
DE60123400T2 (de) 2007-08-23
JP4180826B2 (ja) 2008-11-12
DE60123400D1 (de) 2006-11-09
CA2402213A1 (en) 2001-09-20
US20070269408A1 (en) 2007-11-22
ES2272448T3 (es) 2007-05-01
CN1281748C (zh) 2006-10-25
CA2402213C (en) 2012-08-07
US20040023332A1 (en) 2004-02-05
WO2001068802A2 (en) 2001-09-20
EP1268759A4 (de) 2005-09-28
CN1426464A (zh) 2003-06-25
EP1268759A2 (de) 2003-01-02
US7253151B2 (en) 2007-08-07
EP1268759B1 (de) 2006-09-27
AU3958101A (en) 2001-09-24

Similar Documents

Publication Publication Date Title
DE60123400D1 (de) Gene der il-12p40 untereinheit, welche zur verbesserung der aktivität mutiert sind, und deren verwendung als adjuvans zur dna vakzinierung
Saljoughian et al. Live vaccination tactics: possible approaches for controlling visceral leishmaniasis
Lin et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis
EP1086207A4 (de) Neue methoden und interferon defiziente substrate zur vermehrung von viren
EA200401506A1 (ru) Рекомбинантный поксвирус, экспрессирующий гомологичные гены, встроенные в поксвирусный геном
DE60041280D1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
CY1110964T1 (el) Μεθοδος παραγωγης εμβολιων μεγαλης κλιμακας
DE60303810D1 (de) Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
MX9708854A (es) Terapia de genes para regulacion de celulas efectoras.
ATE507237T1 (de) Replikin-peptide und anwendungen
Chhajer et al. Genetically modified organisms and visceral leishmaniasis
Franková et al. IFN‐γ‐induced TNF‐α is a prerequisite for in vitro production of nitric oxide generated in murine peritoneal macrophages by IFN‐γ
ATE414761T1 (de) Verringerung der virulenz von mycobacterium tuberculosis und tuberkuloseschutz mittels inaktivierung des phop-gens
Calarota et al. IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine
DE60218327D1 (de) Inaktivierte immunogene bakterielle ganzzell-zusammensetzungen
HUP0401585A2 (hu) Fertőző, marhában előforduló, vírusos hasmenés vírusklónja
Lin et al. The co-administrating of recombinant porcine IL-2 could enhance protective immune responses to PRV inactivated vaccine in pigs
BRPI0604365A (pt) polipeptìdeo isolado, composição de vacina anti-carrapato de múltiplas espécies, e, uso dos mesmos
TWI601742B (zh) 使宿主提早產生抗體及延長抗體保護時間的重組雞介白素１β蛋白質及其應用
HUP0402548A2 (hu) Madárembrió-részecskékből álló biomassza vírusantigének előállítására
McGhee et al. IL-12 Is an Effective Adjuvant for Induction
Martínez-Sobrido et al. The Specialized Proresolving Mediator
RU2005104190A (ru) Способ изготовления ассоциированной инактивированной культуральной вакцины против инфекционного ринотрахеита и парагриппа-3 крупного рогатого скота
UA41237A (uk) Спосіб виготовлення вакцинальних алергенів
CZ279159B6 (cs) Avirulentní kmen Trichophyton verrucosum CCM F-765

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties